SB5 is Effective and Safe for Long-Term Psoriasis Treatment
SB5 (adalimumab-bwwd, Hadlima) an FDA-approved adalimumab biosimilar that targets tumor necrosis factor (TNF), was found to be safe, effective, and tolerable in patients with moderate-to-severe psoriasis.1 The long-term, follow-up study included patients …